Get started
Author

Antoine Bonnet

Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group
2016 · E. Tchernonog, P. Faurie, et al. · Annals of Oncology · 135
BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment
2018 · Patricia Gomez-Bougie, Sophie Maiga, et al. · Blood · 81
PDF
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia
2024 · Patrice Chevallier, Thibaut Leguay, et al. · Journal of Clinical Oncology · 53
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study
2019 · Maxime Jullien, Sabrina Trudel, et al. · Annals of Hematology · 34
Safety of ixazomib for the treatment of multiple myeloma
2017 · Antoine Bonnet, Philippe Moreau · Expert Opinion on Drug Safety · 23
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study
2019 · Sabrina Trudel, Benoît Tessoulin, et al. · Annals of Hematology · 17
Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma
2014 · A. Lok, J. Mocquard, et al. · Haematologica · 17
PDF
Clinical presentation, outcome, and prognostic markers in patients with intravascular large B‐cell lymphoma, a lymphoma study association (LYSA) retrospective study
2022 · Antoine Bonnet, Céline Bossard, et al. · Cancer Medicine · 16
PDF
FLT3 ligand plasma levels in acute myeloid leukemia
2019 · Pierre Peterlin, Joelle Gaschet, et al. · Haematologica · 15
PDF
Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System: A Multicentric Cohort Study
2024 · Elodie Berthet, Antoine Guillonnet, et al. · Annals of Neurology · 14
PDF
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort
2023 · Hervé Ghesquières, Fanny Cherblanc, et al. · Blood Advances · 13
PDF
Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma
2018 · Yassine Al Tabaa, Emmanuelle Tchernonog, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 8
Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients
2018 · Louise Bouard, Caroline Bodet-Milin, et al. · Transplantation and Cellular Therapy · 5
Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies
2019 · Louise Bouard, Thierry Guillaume, et al. · Transplantation and Cellular Therapy · 4
Successful treatment of acute promyelocytic leukemia with arsenic trioxide and all-trans retinoic acid in a double lung and kidney transplanted patient
2016 · Pierre Peterlin, Alice Garnier, et al. · Annals of Hematology · 3
Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial.
2025 · Romain Guieze, Emmanuelle Ferrant, et al. · Blood · 2
GPVI as a Potential New Biomarker for Myelofibrosis Diagnosis
2025 · Xavier Hittinger, Yannick Le Bris, et al. · American Journal of Hematology · 2
P1186: a Large French Real World Multicentric Prospective Cohort of Patients With Lymphoma (realysa Study): Description of the Diffuse Large B Cell Lymphoma Patients in Real World in France
2022 · H. Ghesquieres, F. Cherblanc, et al. · HemaSphere · 2
FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia
2019 · Pierre Peterlin, Joelle Gaschet, et al. · Cytokine · 2
PDF
Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries
2025 · Gabriel Brisou, Aurelien Belot, et al. · Blood · 1
Management of Post-Transplant Lymphoproliferative Disorders in the Real Life: The French Attitude Between 2010 and 2013
2016 · Inès Boussen, Caroline Algrin, et al. · Blood · 1
Outcomes of refractory and early‐relapsed large B‐cell lymphoma patients after first‐line treatment in the prospective Real ‐world dAta in LYmphoma patients and Survival in Adults ( REALYSA ) cohort in the pre‐ CAR T era
2026 · Stéphanie Guidez, Aurélien Belot, et al. · British Journal of Haematology
PDF
Valemetostat monotherapy in patients with relapsed or refractory B-cell lymphoma: Final results of the Phase 2 valym study from the lysa
2025 · Emmanuel Bachy, Fontanet Bijou, et al. · Blood
PDF
Excellent outcomes with anti-PD1 therapy in relapsed/refractory primary mediastinal large B-cell lymphoma: Real-world data from the lysa group
2025 · Loïc Renaud, Florian Chevillon, et al. · Blood
PDF
Retromomelo: Real-world use of momelotinib – the french experience from the FIM group
2025 · Mathilde Chanut, Imane Belhadi, et al. · Blood
Works count: 37
Citation count: 448
H-index: 11
I10-index: 11
Year
Topic
Type